NCT04503395 ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
| NCT ID | NCT04503395 |
| Status | Recruiting |
| Phase | — |
| Sponsor | FCRE (Foundation for Cardiovascular Research and Education) |
| Condition | Aortic Aneurysm, Abdominal |
| Study Type | INTERVENTIONAL |
| Enrollment | 204 participants |
| Start Date | 2021-05-21 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 204 participants in total. It began in 2021-05-21 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this randomized study is to compare the safety and performance of EndoVascular Aneurysm Repair with ESAR using Endurant + Heli-FX™ EndoAnchor™ system and FEVAR using customizable grafts from Cook (Zenith Fenestrated Graft) and Terumo (Fenestrated Anaconda Graft) for the treatment of aortic aneurysms with short aortic neck (4 to 15mm).
Eligibility Criteria
Inclusion Criteria: * Subject is \>18 years old * Subject is scheduled for primary treatment of the abdominal aortic aneurysm with a non-aneurysmal infrarenal aortic sealing zone proximal to the aneurysm that is sufficiently healthy for a proximal neck length that is at least 4mm and not more than15 mm and has a circumferential minimum sealing zone length of 8 mm * Subject is not a candidate for safe, effective and durable standard EVAR due to challenging anatomical criteria as confirmed by the Core Lab screening * Subject is able and willing to comply with the protocol and to adhere to the follow-up requirements. * Subject has provided written informed consent CT Angiographic Inclusion Criteria * Subject meets the other anatomical requirements according to the locally applicable Endurant II/IIs stent graft system, Heli-FX EndoAnchor system, Terumo Fenestrated Anaconda (available in EU only) and/or Cook Zenith Fenestrated Graft Instructions for Use * Proximal neck length of the aorta within 4-15mm and a minimum circumferential sealing zone of 8mm * Aortic neck diameter from 19 to 31mm * Infrarenal neck angulation ≤45° Exclusion Criteria: * Subject is participating in a concurrent study which may confound study results * Subject has a life expectancy \<2 year * Subject is female of childbearing potential in whom pregnancy cannot be excluded * Subject with eGFR \<30 mL/min/m2 (KDOQI classification - exclude class IV and above) and or on dialysis * Subject with a MI or CVA within 3 months prior to index procedure * Subject with known Connective Tissue Disease * Subject has a known hypersensitivity or contraindication to anticoagulants, antiplatelets, or contrast media, which is not amenable to post-treatment * Subject who has undergone prior endovascular or open surgical treatment for abdominal aortic aneurysm * Subject requires emergent aneurysm treatment, for example, trauma or rupture * Subject has a known hypersensitivity or allergies to study device implant material * Subject has an aneurysm that is: * Suprarenal, pararenal, or thoracoabdominal * Mycotic * Inflammatory * Pseudoaneurysm * Subject is presenting with thrombus or calcification of the proximal aneurysm neck: circumferential \>50% * Pre-op stenosis of the renal arteries \> 50% * Subject has active infection or history of COVID-19. History of COVID-19 is defined as availability of positive COVID-19 test with sequelae or hospitalization for treatment of COVID-19.
Contact & Investigator
Giovanni Torsello, Prof. Dr.
PRINCIPAL INVESTIGATOR
Vascupedia
Frequently Asked Questions
Who can join the NCT04503395 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Aortic Aneurysm, Abdominal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04503395 currently recruiting?
Yes, NCT04503395 is actively recruiting participants. Contact the research team at info@fcre.eu for enrollment information.
Where is the NCT04503395 trial being conducted?
This trial is being conducted at La Jolla, United States, Stanford, United States, Gainesville, United States, Grand Rapids, United States and 11 additional locations.
Who is sponsoring the NCT04503395 clinical trial?
NCT04503395 is sponsored by FCRE (Foundation for Cardiovascular Research and Education). The principal investigator is Giovanni Torsello, Prof. Dr. at Vascupedia. The trial plans to enroll 204 participants.